The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma

• Published in: Journal of cancer research and clinical oncology 2012-04, Vol.138 (4), p.637-646
• Main Authors: Jiang, Chengying, Hu, Fangke, Tai, Yanhong, Du, Jingli, Mao, Beibei, Yuan, Zengqiang, Wang, Yan, Wei, Lixin
• Format: Article
• Language: English
• Subjects: Adult; Antineoplastic agents; Biological and medical sciences; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Blotting, Western; Cancer; Cancer Research; Carcinoma, Hepatocellular - genetics; Carcinoma, Hepatocellular - metabolism; Carcinoma, Hepatocellular - pathology; Gastroenterology. Liver. Pancreas. Abdomen; Gene Expression Regulation, Neoplastic; Hematology; Hepatocellular carcinoma; Homology; Humans; Immunohistochemistry; Internal Medicine; Kaplan-Meier Estimate; Liver Neoplasms - genetics; Liver Neoplasms - metabolism; Liver Neoplasms - pathology; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Malignancy; Medical sciences; Medicine; Medicine & Public Health; Microarray Analysis - statistics & numerical data; Middle Aged; Multivariate Analysis; Neoplasm Staging; Oncology; Original Article; Pharmacology. Drug treatments; Phosphorus content; Polymerase chain reaction; Prognosis; Proportional Hazards Models; Protein Tyrosine Phosphatase, Non-Receptor Type 11 - genetics; Protein Tyrosine Phosphatase, Non-Receptor Type 11 - metabolism; Protein-tyrosine-phosphatase; Proto-oncogenes; Reverse Transcriptase Polymerase Chain Reaction; Src protein; Survival; Tumor suppressor genes; Tumor Suppressor Proteins - genetics; Tumor Suppressor Proteins - metabolism; Tumors; Western blotting
• ISSN: 0171-5216; 1432-1335
• DOI: 10.1007/s00432-011-1143-5

Purpose The human gene PTPN11, which encodes the non-receptor protein tyrosine phosphatase of Src homology phosphotyrosine phosphatase 2 (Shp2), has been previously well interpreted as a proto-oncogene in a variety of malignancies. However, the tumor suppressor role of Shp2 has also been reported. The present study was conducted to investigate the role of Shp2 expression and its associated clinical manifestations in hepatocellular carcinoma (HCC). Methods A tissue microarray of 333 pairs of HCC and self-matched adjacent non-tumor tissues was constructed, and the expression of Shp2 was determined by immunohistochemistry. The results were also conformed by Western blotting and quantitative PCR of 31 self-paired fresh HCC specimens. The associations of Shp2 expression with 25 clinicopathologic features were analyzed. Overall survival analysis and multivariate analysis were performed. Results Significantly decreased Shp2 expression in tumor tissues (T) compared with adjacent non-tumor tissues (NT) could be detected, and the positive rate was 66.1 and 96.7%, respectively. We combined the T and NT Shp2 immunoreactivity by a variable of the decrease in Shp2 expression (ΔShp2) and divided cases into 2 groups: T